ライフサイエンスコーパス: severe combined immunodeficient

1 erposition graft in the abdominal aorta of a severe combined immunodeficient Beige mouse model suppor

2 In severe combined immunodeficient beige mouse models of MC

3 an CD19(+) tumors in immunocompromised SCID (severe combined immunodeficient)-Beige mice.

4 tacrolimus, Bonferroni's P<0.001) and in the severe combined immunodeficient-beige mice (117+/-18 in

5 BALB/c mice or severe combined immunodeficient-beige mice were treated

6 lones, grow in soft agar, and form tumors in severe combined immunodeficient-beige mice.

7 fused W6/32 Fab'2 antibody to human HLA into severe combined immunodeficient/beige mice that had been

8 To address this we used nonobese diabetic-severe combined immunodeficient-beta(2) microglobulin kn

9 ion of ospA mRNA was found in tissues of C3H-severe combined immunodeficient (C3H-scid) mice, but not

10 Human fetal lung tissue was implanted into severe combined immunodeficient (CB17-scid) mice and ino

11 Humanized nonobese diabetic severe combined immunodeficient common gamma chain-defic

12 islets under the kidney capsule in diabetic severe combined immunodeficient (d-SCID) mice.

13 s to restore euglycemia in nonobese diabetic/severe combined immunodeficient diabetic recipients was

14 the recurrence of autoimmune diabetes in NOD/severe combined immunodeficient disease (SCID) islet iso

15 al vein of either C57BL/6 (DNA-PKcs(+/+)) or severe combined immunodeficient (DNA-PKcs(-/-)) mice.

16 Nonobese diabetic severe combined immunodeficient gammac(-/-) (NSG) mice r

17 self-antigen-specific CTLs in vitro and in a severe combined immunodeficient-hu mouse model.

18 In contrast to nonobese diabetic severe combined immunodeficient Il2rg(-/-) (NSG) mice, h

19 f immunocompetent limited flora (I-LF) mice, severe combined immunodeficient limited flora (SCID-LF)

20 antation of these cells in nonobese diabetic-severe combined immunodeficient mice (a) generated xenog

21 fts in three genetically isolated strains of severe combined immunodeficient mice (C.B-17, C57BL/6J,

22 uction of the human HGF ligand in transgenic severe combined immunodeficient mice (hHGF(tg)-SCID mice

23 Groups 1 to 4 of severe combined immunodeficient mice (n = 5-7 per group)

24 weeks old abortuses were xenografted s.c. to severe combined immunodeficient mice (n = 52).

25 mum tolerated dose of 2L-Rap-hLL1-gamma4P in severe combined immunodeficient mice (SCID) or BALB/c mi

26 ntitumor effects were markedly diminished in severe combined immunodeficient mice and (b) CD8+ T cell

27 Human fetal bones were implanted in severe combined immunodeficient mice and after 4 weeks,

28 aneously implanted into the left shoulder of severe combined immunodeficient mice and evaluated.

29 nted tumors when transplanted into syngeneic severe combined immunodeficient mice and normal mice.

30 MDMs were injected into the basal ganglia of severe combined immunodeficient mice and then Li was adm

31 e studied the effects of THMAM-MD in vivo in severe combined immunodeficient mice bearing HT-29 colon

32 In nonobese diabetic/severe combined immunodeficient mice bearing human EBV l

33 We found that pretreatment of severe combined immunodeficient mice bearing human intes

34 ncer and significantly prolonged survival of severe combined immunodeficient mice bearing LAPC-4 xeno

35 activity of 8H9(scFv)-PE38 was evaluated in severe combined immunodeficient mice bearing MCF-7 breas

36 In the current study, severe combined immunodeficient mice bearing s.c. tumors

37 In severe combined immunodeficient mice bearing SKOV3 tumor

38 PET/CT small-animal imaging was performed in severe combined immunodeficient mice bearing solid and d

39 Severe combined immunodeficient mice bearing U87MG xenog

40 Severe combined immunodeficient mice bearing uveal melan

41 e drug combination decreased tumor volume in severe combined immunodeficient mice by approximately 60

42 growth and the gain in mean tumor volume in severe combined immunodeficient mice compared with vehic

43 nd engraft immunodeficient nonobese diabetes/severe combined immunodeficient mice during both primary

44 cific neutralizing anti-CXCL12 antibodies to severe combined immunodeficient mice expressing human no

45 on of late-passage H-Ras-expressing cells in severe combined immunodeficient mice formed carcinomas w

46 eplication in nontumor tissues and protected severe combined immunodeficient mice from developing let

47 was used in vivo to treat nonobese diabetic/severe combined immunodeficient mice given injections of

48 Severe combined immunodeficient mice harboring U87 xenog

49 he marrow space of the bone implanted in the severe combined immunodeficient mice implanted with feta

50 0530 profoundly inhibits tumor metastasis in severe combined immunodeficient mice implanted with GRP-

51 An in vivo efficacy trial with severe combined immunodeficient mice implanted with subc

52 ndent growth in vitro and tumor formation in severe combined immunodeficient mice in vivo.

53 implanted as xenografts in nonobese diabetic/severe combined immunodeficient mice in vivo.

54 CDV) and octadecyloxyethyl-CVD (ODE-CDV)--in severe combined immunodeficient mice in which either hum

55 5(+) T cells to infected macrophage-depleted severe combined immunodeficient mice induced CNS demyeli

56 ionship between phospho-AKT and FAS in vivo, severe combined immunodeficient mice injected intraperit

57 meliorated adoptively transferred ileitis in severe combined immunodeficient mice injected with CD4 +

58 Nonobese diabetic severe combined immunodeficient mice lacking the cytokin

59 dies, BMSCs and ECs were cotransplanted into severe combined immunodeficient mice on biodegradable po

60 t study, we induced EAE in T-cell-deficient, severe combined immunodeficient mice or in immunocompete

61 t VEGF111 addition before transplantation to severe combined immunodeficient mice ovaries.

62 th a targeted deletion of the T-bet gene and severe combined immunodeficient mice receiving CD4+ cell

63 er growth was evaluated in hu-PBL-SCID mice (severe combined immunodeficient mice reconstituted with

64 Severe combined immunodeficient mice remained persistent

65 uman ovarian tumor cells into the ovaries of severe combined immunodeficient mice resulted in periton

66 racranial implantation of human gliomas into severe combined immunodeficient mice showed a marked red

67 The standard adoptive transfer study in NOD-severe combined immunodeficient mice showed that periphe

68 Severe combined immunodeficient mice that received purge

69 following immunization of nonobese diabetic-severe combined immunodeficient mice that were repopulat

70 R, and DeltaB-Raf:ER cells to form tumors in severe combined immunodeficient mice was compared.

71 Intratibial tumor injection in severe combined immunodeficient mice was used to simulat

72 cells harvested from carcinoma formation in severe combined immunodeficient mice were designated caM

73 Female severe combined immunodeficient mice were fed a low-fat/

74 Severe combined immunodeficient mice were given injectio

75 When severe combined immunodeficient mice were injected with

76 Severe combined immunodeficient mice were reconstituted

77 Severe combined immunodeficient mice were reconstituted

78 tin-expressing tumors grown as xenografts in severe combined immunodeficient mice were responsive to

79 cTVT fragments grown in severe combined immunodeficient mice were successfully i

80 M21 (human melanoma)-bearing severe combined immunodeficient mice were used for biodi

81 ive, Fc-dependent, passive immunity, even in severe combined immunodeficient mice with an established

82 inst subcutaneous B-cell tumor xenografts in severe combined immunodeficient mice with comparable or

83 HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopul

84 Furthermore, Kp-10 inhibits tumor growth in severe combined immunodeficient mice xenografted with hu

85 Severe combined immunodeficient mice xenografted with M2

86 volume, rate of metastasis, and mortality of severe combined immunodeficient mice xenografted with PC

87 model originating from footpad injection in severe combined immunodeficient mice, 95% of the resulti

88 ondii in BALB/c mice, immunocompetent, or in severe combined immunodeficient mice, and after treatmen

89 ere injected directly into the peritoneum of severe combined immunodeficient mice, and in a syngeneic

90 neither resulted in weight loss nor death in severe combined immunodeficient mice, and pock lesions w

91 the growth of TPras transgenic melanomas in severe combined immunodeficient mice, blocked invasive b

92 model established by tail vein injection in severe combined immunodeficient mice, clonality of lung

93 In severe combined immunodeficient mice, Ebp1 overexpressio

94 sgene expression was substantially higher in severe combined immunodeficient mice, indicating that in

95 as far less efficacious in immunocompromised severe combined immunodeficient mice, indicating the req

96 The severe combined immunodeficient mice, on the other hand,

97 ally injected into the basal ganglia of CB17 severe combined immunodeficient mice, received daily int

98 When Cyno-1 cells were injected into severe combined immunodeficient mice, teratomas with der

99 In severe combined immunodeficient mice, the antitumor effi

100 When injected into the mammary fat pads of severe combined immunodeficient mice, the tumors formed

101 Additionally, in in vivo studies in severe combined immunodeficient mice, there was signific

102 Finally, using an angiogenesis assay in severe combined immunodeficient mice, we demonstrate tha

103 lls, bone marrow chimeras, and reconstituted severe combined immunodeficient mice, we identify the pr

104 ation of SKOV3ip1 cells in nonobese diabetic/severe combined immunodeficient mice, with increased pho

105 In severe combined immunodeficient mice, xenograft tumors e

106 tumor formation and inhibited metastasis in severe combined immunodeficient mice.

107 nt growth in soft agar, and tumorigenesis in severe combined immunodeficient mice.

108 an carcinomas implanted in immunocompromised severe combined immunodeficient mice.

109 ity in prostate cancer tumors implanted into severe combined immunodeficient mice.

110 ompetitive repopulation of nonobese diabetic/severe combined immunodeficient mice.

111 homa cells were intravitreally injected into severe combined immunodeficient mice.

112 ction on PLC/PRF/5 human tumor xenografts in severe combined immunodeficient mice.

113 in soft agar as well as s.c. tumor growth in severe combined immunodeficient mice.

114 on, led to the formation of larger tumors in severe combined immunodeficient mice.

115 sicles in a model of glycerol-induced AKI in severe combined immunodeficient mice.

116 mor cell growth and invasion in vitro and in severe combined immunodeficient mice.

117 and these cells were grown as xenografts in severe combined immunodeficient mice.

118 ibited human CCA cell growth in vitro and in severe combined immunodeficient mice.

119 f resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice.

120 tibody targeted to HER2-expressing tumors in severe combined immunodeficient mice.

121 variant of SN12C) tumors grown in kidneys of severe combined immunodeficient mice.

122 gnals as shown in chimeric nonobese diabetic/severe combined immunodeficient mice.

123 LAPC-4 cells were injected into male severe combined immunodeficient mice.

124 antation into the mammary fat pads of female severe combined immunodeficient mice.

125 -reperfusion-injured adult nonobese diabetic-severe combined immunodeficient mice.

126 ndrogen-independent DU145 prostate cancer in severe combined immunodeficient mice.

127 MET-1 leukemic cells into nonobese diabetic/severe combined immunodeficient mice.

128 s when these cells were inoculated s.c. into severe combined immunodeficient mice.

129 into cardiomyocytes in the injured hearts of severe combined immunodeficient mice.

130 ) from an ATL patient into nonobese diabetic/severe combined immunodeficient mice.

131 colonization potential after injection into severe combined immunodeficient mice.

132 by a neutralizing antibody to human CXCR4 in severe combined immunodeficient mice.

133 econstitute the marrow of non-obese diabetic severe combined immunodeficient mice.

134 ited lung colonization of the tumor cells in severe combined immunodeficient mice.

135 n into the left subrenal capsule of diabetic severe combined immunodeficient mice.

136 ression was studied in nonobese diabetic and severe combined immunodeficient mice.

137 we implanted human-derived glioma cells into severe combined immunodeficient mice.

138 ling of human coronary artery transplants in severe combined immunodeficient mice.

139 nd also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice.

140 or supplemented (GFS) matrigel into diabetic severe combined immunodeficient mice.

141 reotactically injected into the subcortex of severe combined immunodeficient mice.

142 tail vein of MDA-MB-231 tumor-bearing female severe combined immunodeficient mice.

143 sed invasiveness of MCF10.DCIS xenografts in severe combined immunodeficient mice.

144 ng highly invasive HCC in nonobese diabetic, severe combined immunodeficient mice.

145 raftment of these cells in nonobese diabetic/severe combined immunodeficient mice.

146 d not express uPAR formed palpable tumors in severe combined immunodeficient mice; however, metastase

147 asion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor gr

148 owth of malignant mesothelioma xenografts in severe-combined immunodeficient mice and extended host s

149 This report uses severe-combined immunodeficient mice given injections of

150 C1 was seen toward H460 tumor xenografts in severe-combined immunodeficient mice.

151 cells were injected intratibially in C3H and severe-combined immunodeficient mice.

152 line (EGI-1) after xenotransplantation into severe-combined-immunodeficient mice, (3) expression of

153 6Mre11(ATLD1/ATLD1) and C57BL/6(Prkdc/SCID) (severe combined immunodeficient) mice exposed to low-dos

154 ation in soft agar, tumor formation in SCID (severe combined immunodeficient) mice, and adhesion.

155 eotide-binding oligomerization domain)/SCID (severe combined immunodeficient) mice.

156 edium before transfer to Prkdc(scid)-mutant (severe combined immunodeficient) mice.

157 an peripheral blood leukocytes (hu PBL-SCID [Severe Combined Immunodeficient] mice) to test the hypot

158 A human/severe combined immunodeficient mouse chimeric model was

159 prevent progression of established CaP in a severe combined immunodeficient mouse implanted with fet

160 f normal islets in a streptozotocin-diabetic severe combined immunodeficient mouse marginal islet mas

161 The chimeric nonobese diabetic severe combined immunodeficient mouse model may be usefu

162 A severe combined immunodeficient mouse model of extravasa

163 In a severe combined immunodeficient mouse model of human NSC

164 Finally, using a humanized severe combined immunodeficient mouse model of lymphocyt

165 In a severe combined immunodeficient mouse model, PDGF DD exp

166 ithout affecting primary tumorigenicity in a severe combined immunodeficient mouse model.

167 development in a humanized nonobese diabetic-severe combined immunodeficient mouse model.

168 at our in vitro results can be extended to a severe combined immunodeficient mouse model.

169 S.c. xenograft assays were carried out in a severe combined immunodeficient mouse model.

170 cells, using a xenogeneic nonobese diabetic/severe combined immunodeficient mouse model.

171 inant hepatic failure in a nonobese diabetic severe combined immunodeficient mouse model.

172 one B (dEpoB) in xenograft nonobese diabetic/severe combined immunodeficient mouse models with subcut

173 eutic treatments using both cell culture and severe combined immunodeficient mouse models.

174 ound to inhibit pancreatic tumor growth in a severe combined immunodeficient mouse xenograft model.

175 c. human GD2-positive melanoma growth in the severe combined immunodeficient mouse xenograft model.

176 These investigations in a nonobese diabetic severe combined immunodeficient mouse-human neural cell

177 activation of ERK even when passed through a severe combined immunodeficient mouse.

178 dicates that the NOD/SCID (nonobese diabetic/severe combined immunodeficient) mouse model can be a va

179 ta-glucuronidase-deficient nonobese diabetic/severe combined immunodeficient/mucopolysaccharidosis ty

180 geneic graft-versus-host disease (X-GVHD) in severe combined immunodeficient murine recipients of hum

181 bet knockout (KO) mutants, or congenic SCID (severe, combined immunodeficient) mutants were given liv

182 BD islets transplanted to non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice efficien

183 arian carcinoma growth in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice.

184 atocytes when infused into nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice.

185 marrow of immunodeficient nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice.

186 In non-obese diabetic-severe combined immunodeficient (NOD-SCID) recipients, w

187 population with use of the nonobese diabetic/severe combined immunodeficient (NOD/SCID) and NOD/SCID

188 ngraftment of AML cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) animals, and

189 The nonobese diabetic/severe combined immunodeficient (NOD/SCID) assay is the

190 ibialis anterior muscle of nonobese diabetic-severe combined immunodeficient (NOD/SCID) beta 2m(-/-)

191 higher tumor incidence in nonobese diabetic/severe combined immunodeficient (NOD/SCID) Ilgamma2(null

192 Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice accept h

193 selected for passage into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice and mini

194 imaging were done on male nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice bearing

195 is trial transplanted into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice resulted

196 ns in the liver and gut of nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice that und

197 gate the in vivo efficacy, nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice were xen

198 ultiple ALL cell lines and nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice xenograf

199 the retroorbital plexus of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, allowed

200 IM CD34(+) cells engrafted nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, demonst

201 ncreased tumorigenicity in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, possibl

202 xenografts established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, were di

203 f leukemia and survival in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

204 and primary ALL samples in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

205 n the peritoneal cavity of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

206 marrow and the spleens of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

207 Here we report that a new nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse line ha

208 er, when injected into the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse prostat

209 We examined whether the nonobese diabetic/severe combined immunodeficient (NOD/scid) mouse, which

210 A nonobese diabetic/severe combined immunodeficient (NOD/SCID) murine xenogr

211 ll as stem cells using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) xenograft mod

212 Stem cell engraftment into nonobese diabetic-severe combined immunodeficient (NOD/SCID)/beta2m-/- mic

213 (+) B-cell malignancies in nonobese diabetic/severe combined immunodeficient (NOD/SCID)/gamma(c)(null

214 regression was blocked in nonobese diabetic/severe combined immunodeficient (NOD/SCID-gamma) mice, w

215 e therefore developed an in vivo MM model in severe combined immunodeficient/nonobese diabetic mice i

216 rsus FasL(-/-) mouse liver CD8(+) T cells to severe combined immunodeficient or RAG1(-/-) recipient m

217 mis, a nuclease mutated in a subset of human severe combined immunodeficient patients.

218 Immune competent, severe combined immunodeficient, RAG1-deficient, and gre

219 nfected donors expanded in reovirus-infected severe combined immunodeficient recipient mice and media

220 il also improved transduction in human SCID (severe combined immunodeficient) repopulating cell (SRC)

221 In severe combined immunodeficient (SCID) beige mouse model

222 Introduction of BCR-ABL into Arf-null severe combined immunodeficient (SCID) bone marrow proge

223 or its ability to protect wild-type (WT) and severe combined immunodeficient (SCID) C.B-17 mice again

224 uated envelope SU cloned sequences from five severe combined immunodeficient (SCID) foals infected wi

225 raacetic acid (DOTA)-RGD in 20 tumor-bearing severe combined immunodeficient (SCID) mice after a bolu

226 Similarly, VPA protects severe combined immunodeficient (SCID) mice against the

227 titumor effects of MEDI-575 in tumor-bearing severe combined immunodeficient (SCID) mice and in genet

228 xpressed in autoimmune target tissues of NOD/severe combined immunodeficient (scid) mice and of autoi

229 in the brain's extracellular space of C.B.17 severe combined immunodeficient (scid) mice and tumor ce

230 antibody significantly prolonged survival of severe combined immunodeficient (SCID) mice bearing CD70

231 f B-B4-DM1 in 3 human MM models in mice: (1) severe combined immunodeficient (SCID) mice bearing subc

232 e tissues (5-8), two studies have shown that severe combined immunodeficient (SCID) mice can be infec

233 Severe combined immunodeficient (SCID) mice carry a germ

234 iver homogenates after 24 serial passages in severe combined immunodeficient (SCID) mice caused sever

235 ted in urokinase plasminogen activator (uPA)/severe combined immunodeficient (SCID) mice engrafted wi

236 Once the treatment was discontinued, severe combined immunodeficient (SCID) mice had progress

237 -dependent protein kinase (DNA-PK)-defective severe combined immunodeficient (SCID) mice have a great

238 be here a novel in vivo model of human WM in severe combined immunodeficient (SCID) mice implanted wi

239 In severe combined immunodeficient (SCID) mice injected wit

240 vivo binding characteristics were studied in severe combined immunodeficient (SCID) mice inoculated w

241 splantation of purified HSCs into a panel of severe combined immunodeficient (SCID) mice leads to a r

242 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice to induce IT

243 man dorsal root ganglion (DRG) xenografts in severe combined immunodeficient (SCID) mice to investiga

244 Groups of severe combined immunodeficient (SCID) mice were first i

245 Severe combined immunodeficient (SCID) mice were infecte

246 WT) mice were subjected to DNFB-induced CHS, severe combined immunodeficient (SCID) mice were injecte

247 nificantly extends survival of 697 xenograft severe combined immunodeficient (SCID) mice without disc

248 Inoculation of severe combined immunodeficient (SCID) mice yielded isol

249 e was tested for its metastatic potential in severe combined immunodeficient (SCID) mice, by i.v. inj

250 When coinjected with human MM cells into severe combined immunodeficient (SCID) mice, green fluor

251 When implanted subcutaneously in severe combined immunodeficient (SCID) mice, MDA-PCa-118

252 AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting

253 After transplantation into severe combined immunodeficient (SCID) mice, the differe

254 When implanted into severe combined immunodeficient (SCID) mice, the growth

255 ith the cDNA for heparanase are implanted in severe combined immunodeficient (SCID) mice, the resulti

256 or importantly when grown subcutaneously in severe combined immunodeficient (SCID) mice.

257 d prevented the s.c. growth of PC-3 cells in severe combined immunodeficient (SCID) mice.

258 o initiate tumors in nude and hypersensitive severe combined immunodeficient (SCID) mice.

259 nocompetent mice or T-cell-deficient mice to severe combined immunodeficient (SCID) mice.

260 cessfully immunized BALB/c mice to syngeneic severe combined immunodeficient (SCID) mice.

261 erial engraftment in nonobese diabetic (NOD)/severe combined immunodeficient (SCID) mice.

262 mor activity against human MM cell growth in severe combined immunodeficient (SCID) mice.

263 administered intravenously to glioma-bearing severe combined immunodeficient (SCID) mice.

264 scaffolds and implanted subcutaneously into severe combined immunodeficient (SCID) mice.

265 or after coinjection of PA in tumor-bearing severe combined immunodeficient (SCID) mice.

266 rigel, in coculture with fibroblasts, and in severe combined immunodeficient (SCID) mice.

267 ublethally irradiated nonobese diabetic (NOD)severe combined immunodeficient (SCID) mice.

268 ll as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice.

269 and their splenocytes were transferred into severe combined immunodeficient (SCID) mice.

270 The sLLO strain was cleared by severe combined immunodeficient (SCID) mice.

271 In a severe combined immunodeficient (SCID) mouse model of di

272 Using a severe combined immunodeficient (SCID) mouse model of HI

273 e studied hippocampal synaptic function in a severe combined immunodeficient (SCID) mouse model of HI

274 and tumor formation in an immunocompromized severe combined immunodeficient (SCID) mouse model of or

275 Using a severe combined immunodeficient (SCID) mouse model, we d

276 human renal cell carcinoma in an orthotopic severe combined immunodeficient (SCID) mouse model.

277 ntaneous metastasis assay was performed in a severe combined immunodeficient (SCID) mouse model.

278 med by human prostate cancer cell lines in a severe combined immunodeficient (SCID) mouse tibial inje

279 anti-proliferative effects in the human skin-severe combined immunodeficient (SCID) mouse transplant

280 e show that LRP-1 is abundantly expressed in severe combined immunodeficient (SCID) mouse xenografts

281 in psoriasis in an in vivo system using the severe combined immunodeficient (SCID) mouse-human skin

282 Here, using the severe combined immunodeficient (SCID) mouse-psoriasis x

283 RAG1-mutants from severe combined immunodeficient (SCID) patient cells sho

284 ive to adult bone marrow in allogeneic fetal severe combined immunodeficient (SCID) recipients compar

285 fer of CD8 cells from CD4 knockout mice into severe combined immunodeficient (SCID) recipients.

286 ymphocytes and within human thymic grafts in severe combined immunodeficient (SCID)-hu (Thy/Liv) mice

287 tivities of docetaxel both in culture and in severe combined immunodeficient (SCID)-human model of ex

288 we measure the activity of multipotent human severe combined immunodeficient (SCID)-repopulating cell

289 th pleiotrophin also substantially increased severe combined immunodeficient (SCID)-repopulating cell

290 wn in the epithelium-free mammary fat pad of severe combined immunodeficient (SCID)/Beige and nonobes

291 In liver-humanized uPA/severe combined immunodeficient (SCID)/beige mice challe

292 and after transplantation into the livers of severe combined immunodeficient (SCID)/beige mice.

293 g plasmablasts can be enriched in vivo, in a severe combined immunodeficient (SCID)/beige mouse host.

294 (+) PMF CD34(+) cells into nonobese diabetic/severe combined immunodeficient (SCID)/IL-2Rgamma(null)

295 In the human severe combined immunodeficient (SCID-hu) bone model of

296 ed the growth of primary tumors in the human severe combined immunodeficient (SCID-hu) model of myelo

297 ibodies on an ATL model in nonobese diabetic/severe combined immunodeficient (SCID/NOD) wild-type mic

298 (PMNs) and in human intestinal xenografts in severe-combined immunodeficient (SCID-HU-INT) mice, a no

299 um antibodies to the systemic compartment of severe-combined-immunodeficient (SCID) mice temporarily

300 C57BL/6J or C57BL/6-Prkdc(scid) (severe combined immunodeficient [SCID]) mice were inocul